orantinib has been researched along with pyrimethamine in 2 studies
| Studies (orantinib) | Trials (orantinib) | Recent Studies (post-2010) (orantinib) | Studies (pyrimethamine) | Trials (pyrimethamine) | Recent Studies (post-2010) (pyrimethamine) |
|---|---|---|---|---|---|
| 110 | 19 | 36 | 5,088 | 738 | 1,047 |
| Protein | Taxonomy | orantinib (IC50) | pyrimethamine (IC50) |
|---|---|---|---|
| Dihydrofolate reductase | Homo sapiens (human) | 3.1057 | |
| Dihydrofolate reductase | Bos taurus (cattle) | 0.1007 | |
| Beta-hexosaminidase subunit alpha | Homo sapiens (human) | 6.8333 | |
| Beta-hexosaminidase subunit beta | Homo sapiens (human) | 6.4 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 4.3 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium falciparum K1 | 0.0609 | |
| Dihydrofolate reductase | Pneumocystis carinii | 3.25 | |
| Dihydrofolate reductase | Candida albicans | 5 | |
| Low molecular weight phosphotyrosine protein phosphatase | Homo sapiens (human) | 15.615 | |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | 0.39 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 0.3217 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium falciparum 3D7 | 2.48 | |
| Dihydrofolate reductase | Rattus norvegicus (Norway rat) | 2.0727 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bailey-Downs, LC; Gangjee, A; Ihnat, MA; Kisliuk, RL; Thorpe, JE; Zhao, Y | 1 |
2 other study(ies) available for orantinib and pyrimethamine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Drug Screening Assays, Antitumor; Humans; Indenes; Melanoma, Experimental; Mice; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta | 2012 |